Posted by admin on Jul 30th, 2022

InVivo Therapeutics (NASDAQ:NVIV – Get Rating) and Artivion (NYSE:AORT – Get Rating) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, analyst recommendations, earnings, dividends, profitability, institutional ownership and valuation.

This table compares InVivo Therapeutics and Artivion’s net margins, return on equity and return on assets.

InVivo Therapeutics has a beta of 1.29, indicating that its stock price is 29% more volatile than the S&P 500. Comparatively, Artivion has a beta of 1.42, indicating that its stock price is 42% more volatile than the S&P 500.

This is a summary of recent recommendations and price targets for InVivo Therapeutics and Artivion, as provided by MarketBeat.com.

Artivion has a consensus price target of $27.00, indicating a potential upside of 37.76%. Given Artivion’s higher possible upside, analysts plainly believe Artivion is more favorable than InVivo Therapeutics.

18.6% of InVivo Therapeutics shares are owned by institutional investors. Comparatively, 81.0% of Artivion shares are owned by institutional investors. 0.1% of InVivo Therapeutics shares are owned by company insiders. Comparatively, 5.6% of Artivion shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

This table compares InVivo Therapeutics and Artivion’s top-line revenue, earnings per share and valuation.

InVivo Therapeutics has higher earnings, but lower revenue than Artivion. Artivion is trading at a lower price-to-earnings ratio than InVivo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Artivion beats InVivo Therapeutics on 9 of the 12 factors compared between the two stocks.

InVivo Therapeutics Holdings Corp., a research and clinical-stage biomaterials and biotechnology company, engages in developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries (SCI). It is developing a Neuro-Spinal Scaffold implant, which is an investigational bioresorbable polymer scaffold that is designed for implantation at the site of injury within a spinal cord to treat acute SCI. The company was incorporated in 2003 and is headquartered in Cambridge, Massachusetts.

Artivion Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company offers BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and E-vita Open Plus and E-vita Open Neo. It also provides E-xtra design engineering systems for the treatment of aortic vascular diseases; E-nside, an off-the-shelf stent graft for the treatment of thoraco-abdominal disease; E-vita THORACIC 3G for the endovascular treatment of thoracic aortic aneurysms; E-nya, a thoracic stent graft system for the minimally invasive repair of lesions of the descending aorta; E-ventus BX, a balloon-expandable peripheral stent graft for the endovascular treatment of renal and pelvic arteries; E-liac to treat aneurysmal iliac arteries, and aneurysmal iliac side branches; and E-tegra, an abdominal aortic aneurysms stent graft system. In addition, the company offers synthetic vascular grafts for use in open aortic and peripheral vascular surgical procedures; PerClot, an absorbable powdered hemostat for use in surgical procedures; cardiac laser therapy products for angina treatment; CryoVein femoral vein and CryoArtery femoral artery vascular preservation services; On-X prosthetic aortic and mitral heart valves and the On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters and Chord-X ePTFE sutures for mitral chordal replacement; and ascyrus medical dissection stents, as well as pyrolytic carbon coating services to medical device manufacturers. It serves physicians, hospitals, and other healthcare facilities, as well as cardiac, vascular, thoracic, and general surgeons. The company was formerly known as CryoLife, Inc. and changed its name to Artivion Inc. in January 2022. The company was founded in 1984 and is headquartered in Kennesaw, Georgia.

Receive News & Ratings for InVivo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InVivo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Comparing Five Point (NYSE:FPH) & Keppel REIT (OTCMKTS:KREVF)